ATE428403T1 - Stabilisierte azithromycin-zusammensetzungen - Google Patents

Stabilisierte azithromycin-zusammensetzungen

Info

Publication number
ATE428403T1
ATE428403T1 AT02801784T AT02801784T ATE428403T1 AT E428403 T1 ATE428403 T1 AT E428403T1 AT 02801784 T AT02801784 T AT 02801784T AT 02801784 T AT02801784 T AT 02801784T AT E428403 T1 ATE428403 T1 AT E428403T1
Authority
AT
Austria
Prior art keywords
azithromycin
compositions
stabilized
stabilized azithromycin
antioxidant
Prior art date
Application number
AT02801784T
Other languages
English (en)
Inventor
Ruth Tenengauzer
Joseph Schwarz
Julia Hrakovsky
Tania Lessen
Lev Khondo
Mathi Mathivanan
Claude Singer
Michael Pesachovich
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE428403T1 publication Critical patent/ATE428403T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT02801784T 2001-10-18 2002-10-18 Stabilisierte azithromycin-zusammensetzungen ATE428403T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33634601P 2001-10-18 2001-10-18
US33193101P 2001-11-21 2001-11-21
US34129501P 2001-12-17 2001-12-17
PCT/US2002/033339 WO2003032922A2 (en) 2001-10-18 2002-10-18 Stabilized azithromycin compositions

Publications (1)

Publication Number Publication Date
ATE428403T1 true ATE428403T1 (de) 2009-05-15

Family

ID=27406829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801784T ATE428403T1 (de) 2001-10-18 2002-10-18 Stabilisierte azithromycin-zusammensetzungen

Country Status (12)

Country Link
US (3) US6764997B2 (de)
EP (1) EP1446010B1 (de)
AT (1) ATE428403T1 (de)
AU (1) AU2002335087A1 (de)
CA (1) CA2463619C (de)
DE (1) DE60232005D1 (de)
DK (1) DK1446010T3 (de)
ES (1) ES2324527T3 (de)
HU (1) HUP0402291A2 (de)
IL (1) IL161398A0 (de)
PT (1) PT1446010E (de)
WO (1) WO2003032922A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60209704T2 (de) 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
CA2517004A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
EP1606299A1 (de) * 2003-03-25 2005-12-21 Teva Pharmaceutical Industries Ltd. Azithromycin-abbauprodukte, verfahren zu ihrer identifizierung
WO2004092736A2 (en) * 2003-04-17 2004-10-28 Sandoz Ag Derivatives of azithromycin
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005030257A2 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CA2591744A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
US8906823B2 (en) * 2007-09-24 2014-12-09 Basf Corporation Pollutant emission control sorbents and methods of manufacture and use
TWI592159B (zh) 2007-11-16 2017-07-21 威佛(國際)股份有限公司 藥學組成物
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2011015219A1 (en) 2009-08-06 2011-02-10 Shifa Pharmed Industrial Group Co. Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers
RU2512683C2 (ru) 2012-06-08 2014-04-10 Общество с ограниченной ответственностью "ВИК-здоровье животных" Антибактериальная инъекционная фармацевтическая композиция
CN110809471A (zh) 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
RU2666607C1 (ru) * 2017-05-03 2018-09-11 Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" Способ повышения стабильности инъекционной фармацевтической композиции
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
CN111450065B (zh) * 2020-04-22 2022-04-01 南京嘉晨医药科技有限公司 一种阿奇霉素干混悬剂的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
AU4399396A (en) * 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CN1205338A (zh) * 1998-05-08 1999-01-20 刘万忠 阿奇霉素水溶性盐的合成新方法及其在医药上的用途
US6239112B1 (en) 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US6365574B2 (en) 1998-11-30 2002-04-02 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico

Also Published As

Publication number Publication date
WO2003032922A3 (en) 2003-10-16
PT1446010E (pt) 2009-06-08
WO2003032922A2 (en) 2003-04-24
HK1067278A1 (en) 2005-04-08
AU2002335087A1 (en) 2003-04-28
DK1446010T3 (da) 2009-06-22
EP1446010B1 (de) 2009-04-15
US6764997B2 (en) 2004-07-20
US20030176369A1 (en) 2003-09-18
DE60232005D1 (de) 2009-05-28
HUP0402291A2 (hu) 2005-03-29
ES2324527T3 (es) 2009-08-10
EP1446010A4 (de) 2007-06-13
EP1446010A2 (de) 2004-08-18
US20040192622A1 (en) 2004-09-30
CA2463619C (en) 2008-05-06
IL161398A0 (en) 2004-09-27
US20050106239A1 (en) 2005-05-19
CA2463619A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
DK1446010T3 (da) Stabiliseret azithromycin-sammensætning
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ATE269079T1 (de) Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans
EA200301275A1 (ru) Капсулы для ингаляции
DE69923471D1 (de) Injizierbare propofol-formulierungen
BR9709551A (pt) Composicões de limpeza ácidas contendo goma de xantano
EP2298287A3 (de) Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
NO20025954D0 (no) Glykopeptidfosfonatderivater
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
CY1105009T1 (el) Συνθεση καχαλαλιδης f
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
BRPI0403461A (pt) composições estabilizadas contendo um agente ativo lábil ao oxigênio
MXPA03011128A (es) Composicion de sabor y fragancia.
IL157849A0 (en) Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
EP1541134A3 (de) Stabilisierte Azithromycin-Zusammensetzungen
ATE364619T1 (de) Tibolonformulierungen
WO2002026324A3 (en) Tocol-based compositions containing amiodarone
TNSN03036A1 (en) Stabilized brivudine topical formulations
MXPA03010821A (es) Composiciones de aroma y fragancias.
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
BRPI0406466A (pt) Composição oral e uso de perlita
AU2001287673A1 (en) Novel trioxepan compounds
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
ITMI20011561A0 (it) Nuove composizioni con fosfolipidi biologicamente attivi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties